Pharmaceuticals, Biotechnology and Life Sciences
— Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of…
Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc.…
The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology This…
Increasing visibility of potential study participants to sites and sponsors DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug…
On Track to Initiate Phase 1b Clinical Trial of Topical Drop Formulation of AKB-9778 for Primary Open-Angle Glaucoma (POAG) in…
–Conference Call and Webcast Today at 8:00 a.m. ET– WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused…
YCGP’s “With Love, Me” Letters Campaign Brings Together Cancer Survivors and Caregivers to Share Their Heartfelt Personal Stories with Others…
Phase 2 gMG long-term extension data show durability of zilucoplan treatment effect, with sustained improvements in primary and secondary endpoints…
An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of…
PRINCETON, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt; lt;a href="https://twitter.com/hashtag/BMS?src=hash" target="_blank"gt;#BMSlt;/agt;–Bristol-Myers Squibb Company (NYSE: BMY) today announced the Phase 3 CheckMate -498 trial…